Avalo Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Avalo Therapeutics has a total shareholder equity of $22.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $98.5M and $75.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$81.86m |
| Equity | US$22.73m |
| Total liabilities | US$75.72m |
| Total assets | US$98.46m |
Recent financial health updates
Recent updates
Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007
Aug 01Avalo Therapeutics announces one-for-twelve reverse stock split
Jul 06Is Cerecor (NASDAQ:CERC) A Risky Investment?
Aug 10
Cerecor enters into $35M debt financing agreement with Horizon Technology Finance
Jun 07What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?
Mar 10Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?
Jan 18Armistice Capital adds 2.5M Cerecor shares for $6.5M
Jan 13Cerecor slumps 12% on stock and pre-funded warrants offering
Jan 07Financial Position Analysis
Short Term Liabilities: AVTX's short term assets ($86.1M) exceed its short term liabilities ($60.7M).
Long Term Liabilities: AVTX's short term assets ($86.1M) exceed its long term liabilities ($15.0M).
Debt to Equity History and Analysis
Debt Level: AVTX is debt free.
Reducing Debt: AVTX has no debt compared to 5 years ago when its debt to equity ratio was 84%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AVTX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 12.2% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:25 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avalo Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Louise Chen | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |